↓ Skip to main content

Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma

Overview of attention for article published in Cancer Immunology, Immunotherapy, September 2004
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

patent
5 patents

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
27 Mendeley
Title
Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma
Published in
Cancer Immunology, Immunotherapy, September 2004
DOI 10.1007/s00262-004-0587-8
Pubmed ID
Authors

Peter Hersey, Scott W. Menzies, Brendon Coventry, Tam Nguyen, Margaret Farrelly, Susan Collins, Debbie Hirst, Heather Johnson

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 30%
Student > Master 5 19%
Researcher 5 19%
Professor 1 4%
Student > Bachelor 1 4%
Other 1 4%
Unknown 6 22%
Readers by discipline Count As %
Medicine and Dentistry 9 33%
Agricultural and Biological Sciences 7 26%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Biochemistry, Genetics and Molecular Biology 1 4%
Nursing and Health Professions 1 4%
Other 0 0%
Unknown 7 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2022.
All research outputs
#4,901,379
of 23,563,389 outputs
Outputs from Cancer Immunology, Immunotherapy
#517
of 2,945 outputs
Outputs of similar age
#10,148
of 61,236 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#3
of 16 outputs
Altmetric has tracked 23,563,389 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,945 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 61,236 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.